FDA Conditionally Accepted Name for Lirafugratinib

The FDA has pre-approved the name LYRFIGTU for the experimental anticancer medication.

Updated on Sept. 21, 2026 in Cancer

Bold flat-color editorial illustration of an abstract molecular structure, representing pharmaceutical research and regulatory approval. — The U.S. Food and Drug Administration has conditionally accepted the brand name LYRFIGTU for Lirafugratinib, a targeted oral medication for bile duct cancer. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to prioritize patient health over branding in drug development?

The U.S. Food and Drug Administration has conditionally accepted the brand name LYRFIGTU for Lirafugratinib, an oral small-molecule agent designed to target bile duct cancer. This decision marks a final regulatory step ahead of the agency's upcoming approval deadline.

Why it matters

Lirafugratinib targets specific FGFR2 mutations to inhibit cancer growth, offering a potential new treatment option for patients with bile duct cancer. The FDA designation underscores the clinical significance of the drug’s development path.

Clinical trials for the oral agent demonstrated a 46.5 percent objective response rate among patients with bile duct cancer. The treatment also maintained a median response duration of 11.8 months.

The players

Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and biological products.

Lirafugratinib

This is an experimental oral small-molecule targeted anticancer agent currently undergoing regulatory review for its potential to treat bile duct cancer.

The details

Developed under FDA naming guidelines, the name LYRFIGTU was chosen specifically to highlight the drug's selectivity for FGFR2. If approved, the medication will enter the market as an innovative targeted therapy following several years of fast-track regulatory designations.

Lirafugratinib received Orphan Drug designation in 2022.
The FDA granted Innovative Therapy status in 2023.
Priority Review was granted to the drug in March 2026.
The FDA conditionally accepted the product name on September 21, 2026.
A final FDA approval decision is scheduled for September 25, 2026.

The Big Picture

The development trajectory of this treatment follows a pattern set by the FDA Orphan Drug designation program, which is designed to expedite the path for therapies targeting rare and severe medical conditions.

If approved, this medication will provide a new targeted treatment option for patients with specific genetic mutations associated with bile duct cancer. Physicians and patients will be able to access the drug under the brand name LYRFIGTU once it receives final market authorization.

The takeaway

The conditional naming of this drug suggests the manufacturer and regulators are nearing the final stages of the drug approval process. Patients should consult their oncologists to determine if new targeted therapies like this may align with their specific cancer markers.